Lapatynib (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lapatynib" in Polish language version.

refsWebsite

Global rank Polish rank

4^th place

7^th place

2^nd place

6^th place

1aspetjournals.org

6,663^rd place

7,639^th place

2,374^th place

2,071^st place

low place

low place

68^th place

31^st place

aspetjournals.org

molpharm.aspetjournals.org

W.C. Teng, J.W. Oh, L.S. New, M.D. Wahlin i inni. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. „Mol Pharmacol”. 78 (4), s. 693–703, 2010. DOI: 10.1124/mol.110.065839. PMID: 20624855.

doi.org

W.C. Teng, J.W. Oh, L.S. New, M.D. Wahlin i inni. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. „Mol Pharmacol”. 78 (4), s. 693–703, 2010. DOI: 10.1124/mol.110.065839. PMID: 20624855.
Geyer CE, Forster J, Lindquist D, Chan S. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. „N Engl J Med”. 355 (26), s. 2733–2743, 2006. DOI: 10.1056/NEJMoa064320. PMID: 17192538.

europa.eu

ema.europa.eu

Lapatynib. Streszczenie EPAR dla ogółu społeczeństwa. European Medicines Agency, 2013. [dostęp 2014-09-26].

nejm.org

Geyer CE, Forster J, Lindquist D, Chan S. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. „N Engl J Med”. 355 (26), s. 2733–2743, 2006. DOI: 10.1056/NEJMoa064320. PMID: 17192538.

nih.gov

ncbi.nlm.nih.gov

W.C. Teng, J.W. Oh, L.S. New, M.D. Wahlin i inni. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. „Mol Pharmacol”. 78 (4), s. 693–703, 2010. DOI: 10.1124/mol.110.065839. PMID: 20624855.
Geyer CE, Forster J, Lindquist D, Chan S. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. „N Engl J Med”. 355 (26), s. 2733–2743, 2006. DOI: 10.1056/NEJMoa064320. PMID: 17192538.
J.R. Kroep, S.C. Linn, E. Boven, H.J. Bloemendal i inni. Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer. „Neth J Med”. 68 (9), s. 371–376, 2010. PMID: 20876920.

njmonline.nl

J.R. Kroep, S.C. Linn, E. Boven, H.J. Bloemendal i inni. Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer. „Neth J Med”. 68 (9), s. 371–376, 2010. PMID: 20876920.